AYOXXA Biosystems GmbH, a start-up company based in Cologne (Germany) and Singapore, has developed a novel technology for multiplexed protein analysis. Its business model might be compared with iTunes. Similar to a mobile device like the iPhone, AYOXXA’s biochips can be fitted with a broad range of bioassays applications. The chip will include biomarker content provided by AYOXXA as well as novel antibody panels from development partners. Core of its patented innovation are the so called “in-situ encoded bead arrays” (IEBA). They enable the measurement of a large number of different proteins and biomolecular analytes with high accuracy using very low sample volumes. This technology will benefit many disciplines including biomedical research and pharmacological screening. To date, AYOXXA has already received numerous Awards.


First four companies selected to participate in the German Accelerator Life Sciences program in Cambridge

During the 34th JP Morgan Healthcare Conference, the German Accelerator Life Sciences (GALS) announced the first four companies to participate in its Cambridge-based program. AYOXXA Biosystems, PEPperPRINT, Personal MedSystems, and Sonormed will receive support tailored towards the specific needs of each company for…

HTGF portfolio company AYOXXA BIOSYSTEMS Extends Series B

Andreas Richter new CFO of AYOXXA    AYOXXA Biosystems GmbH, an international biotechnology company, announces the closing of a third round of Series B financing, bringing the total amount raised to 11.3 Mio. EUR in 2014. An additional 2.3 Mio. EUR were now invested by BioMedPartners AG, Basel and Grazia Equity…

HTGF portfolio company AYOXXA Biosystems wins new investors to close a € 9,0m Series B round

AYOXXA Biosystems GmbH, an international biotechnology company, completed a € 9,0m Series B financing round by the end of June 2014. All of the company’s existing investors (High-Tech Gründerfonds, KFW, NRW.BANK, Wellington Partners Venture Capital and private investors) took part, along with new investors b-to-v…

AyoxxA Biosystems Closes Series A Financing Round

2.6 million Euro financing will accelerate development of cutting-edge technology for protein analysis AyoxxA Biosystems, an international biotechnology company, today announces it has closed a 2.6 million Euro Series A financing round. The round was led by Wellington Partners Venture Capital and included NRW.BANK,…

Info & Contact

Rodney Turner, CEO


Nattermannallee 1
50829 Köln

In portfolio

22. Dec 2011